Germany - Immunosuppressants

Description

Conclusion of a non-exclusive discount agreement pursuant to Section 130a (8) SGB V on drugs with the active ingredient certolizumab pegol (ATC code: L04AB05) within the period from November 1, 2023 to October 31, 2025 with the possibility of concluding the agreement at any time during the term ("open-house model").
The AOK Lower Saxony. Health Insurance Fund intends to conclude non-exclusive drug discount contracts for the active ingredient certolizumab pegol (ATC code: L04AB05) with as many market participants as possible (pharmaceutical entrepreneurs or communities of pharmaceutical entrepreneurs) in the so-called "open-house model" until the entry into force of exclusive contracts following a public invitation to tender in accordance with the regulations of Part 4 of the ARC.The AOK Lower Saxony will not make a selection decision and will submit an identical contract offer to each interested pharmaceutical company. In the open-house model, uniform conditions apply to all participants. Contract content, conditions and access procedures are uniform - individual negotiations are generally not conducted. The contract periods are a maximum of twenty-four months; the earliest contract start date is November 1, 2023. All contracts end no later than October 31, 2025, regardless of the date on which the respective contract is concluded. Within the twenty-four-month period, a member may join or conclude a contract on the first day of any month. There is a right of termination six weeks to the end of each month. The AOK Lower Saxony reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts already during the term of the contract. When advertised, exclusive discount contracts come into force, the open-house contracts are terminated in accordance with the contractual regulations, i.e. the open-house contracts end automatically. According to the experience of the AOK Lower Saxony, exclusive rebate contracts usually enter into force six to eight months after publication of the corresponding tender notice in the Supplement to the Official Journal of the European Union. The future contract partners in the open-house model are requested to inform themselves regularly about these tender notices in the Supplement to the Official Journal of the European Union.Interested pharmaceutical companies can request the contract documents as well as the contract terms and conditions at the contact address mentioned under I.1).Contracts for the active ingredient certolizumab pegol (ATC code: L04AB05) will be concluded for the first time with effect from November 1, 2023. Interested parties wishing to become contract partners on this date must submit the contract documents to be submitted by 27.09.2023 to the address stated in the contract documents. The date of receipt by the AOK Lower Saxony is decisive. Later contract conclusions are possible during the twenty-four-month maximum term on the first of each month. Organizationally, a lead time of usually 35 calendar days is necessary on the part of the AOK in order to be able to guarantee the necessary work, e.g. the contract registration in the Lauer-Taxe®. The exact deadlines for receipt will be announced with the contract documents. This publication does not constitute the award of a public contract within the meaning of Directive(2014/24/EU) or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contract conclusions, the publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice is used. The resulting conceptual specifications, such as the procedural designation "open procedure", are solely due to the use of this publication form and the publication platform. A further meaning, in particular a subjection to subcontracting regulations, as far as they are not obligatory for legal reasons, is not connected with it.

Opportunity closing date

27 August 2025

Value of contract

to be confirmed